Overview

OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

Status:
RECRUITING

Trial end date:
2031-03-19

Target enrollment:

Participant gender:

Summary

The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp\[a\]).

Phase:

PHASE3

Details

Lead Sponsor:

Amgen

Treatments:

olpasiran